Newsroom

Industry News

21 Dec

Zomedica Pharmaceuticals Corp. Enters into License and Supply Agreement with Celsee, Inc. for Cancer Liquid Biopsy Platform

ANN ARBOR, Mich., Dec. 21, 2017 (GLOBE NEWSWIRE) — Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (ZOM.V) (“Zomedica” or “Company”), a veterinary pharmaceutical and diagnostic company, today announced it has entered into a license and supply agreement with Celsee, Inc. (“Celsee”), an innovator of progressive rare cell capture, characterization and retrieval products in...

Read more

21 Dec

Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075

Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity SAN DIEGO, Dec. 21, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of the second clinical trial site for its...

Read more

20 Dec

Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the pricing of an underwritten public offering of 1,105,263 shares of its common stock, offered at a price...

Read more

19 Dec

Youngevity To Ring Nasdaq Stock Market Opening Bell on January 3, 2018

SAN DIEGO, CA and New York, NY, Dec. 19, 2017 (GLOBE NEWSWIRE) — Youngevity® International, Inc. (NASDAQ: YGYI), a leading omni-direct lifestyle company, today announced it will ring in the new year on January 3, 2018 at The Nasdaq Stock Market Opening Bell ceremony at the Nasdaq MarketSite in Times Square. In celebration of Nasdaq’s...

Read more

15 Dec

Trovagene Prices $4.5 Million Public Offering

SAN DIEGO, Dec. 15, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the pricing of a public offering of 15,000,000 shares of its common stock (or common stock equivalents) and common warrants to purchase up to an aggregate of 15,000,000 shares of common stock. Each share...

Read more

14 Dec

The Crypto Company Announces 10-For-1 Stock Split After Rapid Growth

LOS ANGELES, Dec. 13, 2017 (GLOBE NEWSWIRE) — The Crypto Company (CRCW), one of the first publicly traded companies in the digital currencies and blockchain sector, today announced plans to execute a 10-for-1 stock split. The company’s shares, currently trading on Over-The-Counter (OTC) markets under the CRCW ticker, experienced a recent...

Read more

14 Dec

OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab

SAN DIEGO, Dec. 14, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695, the company’s global, multi-center, registration-directed open-label Phase 2b clinical trial. The trial will evaluate the combination of ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid...

Read more

14 Dec

Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer

PCM-075, Trovagene’s Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represent a novel combination treatment option in mCRPC SAN DIEGO, Dec. 14, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing...

Read more

Page 3 of 27612345...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address